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ABSTRACT 
A novel reverse phase HPLC assay method has been developed and validated for the simultaneous determination of Gemcitabine 
Hydrochloride (dFdCH) along with solid lipid nanoparticles SLNs and conjugated with mannose to targeting the lungs for 
chemotherapy. Methanol was used as the extracting solvent for preparation of tissue sample. Methanol: Ammonium acetate buffer; 
10:90 v/v (pH 5) was the mobile phase at flow rate 1.5 mL/min at pressure of 102/101 bars using Luna Phenomenex, C18 
(4.6mm×250 mm; 5 µm bead size) at wavelength 269 nm. The column oven temperature was optimized at 350C. The biodistribution 
studies were conducted to evaluate the target potential at the sites of interest in liver, spleen, lung and kidney respectively, the 
calibration curve was found to be linear over the concentration range of 100-5000 ng/mL(r2=0.9980, r2=0.9980, r2=0.9990, r2=1 
respectively). Plain drug have greatest access to liver and secondarily to spleen and then kidney but on the contrary the concentration 
of drug was greatest in lung when treated with mannosylated SLNs, data suggested that the mannose attachment has provided the 
access for the drug in the lungs via the formulation in greater quantity than free drug due to interaction of mannose with mannose 
receptors present on lung macrophages. The developed method was validated in accordance to ICH guidelines. 
Keywords: High Performance Liquid Chromatography, Mannosylated SLNs, Macrophage Mannose, Receptor (MMR), Lung 
Cancer, Gemcitabine Hydrochloride. 
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INTRODUCTION 
Gemcitabine is a pyrimidine antimetabolite. Chemically 
it is 2’-2’-difluorodeoxycitidine (dFdC). This molecule 
bearing fluorine atom replaces the hydroxyl group and 
the hydrogen atom at the 2’-position of cytidine. After 
its anabolism to diphosphate and triphosphate 
metabolites, gemcitabine inhibits ribonucleotide 
reductase and competes with 2’ – deoxycytidine 
triphosphate for incorporation into DNA. These effects 
produce cell-cycle-specific cytotoxicity. 
1-2 
Selective and site-specific administration of anticancer 
drugs may help in overcoming low survival rate and 
cytotoxic effects on normal tissues. Even highly toxic 
agents could be rendered safer and more effective, if it 
could be possible to direct them specifically into the 
tumor cells. This is because of accomplishment of higher 
drug concentration within the tumor cells, with fewer or 
no distribution towards normal tissues. To achieve the 
above mentioned goal we planned to construct mannose 
anchored SLNs nano-constructs loaded with anticancer 
bioactive for efficiently targeting the lung cancer cells. 
3-
7
        
SLNs are typically spherical with an average diameter 
between 10 and 1000 nanometers. Solid lipid 
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nanoparticles possess a solid lipid core matrix that can 
solubilize lipophilic molecules. The lipid core is 
stabilized by surfactants (emulsifiers). The term lipid is 
used here in a broader sense and includes triglycerides 
(e.g. tristearin), diglycerides (e.g. glycerol bahenate), 
monoglycerides (e.g. glycerol monostearate), fatty acids 
(e.g. stearic acid), steroids (e.g. cholesterol), and waxes 
(e.g. cetyl palmitate). All classes of emulsifiers (with 
respect to charge and molecular weight) have been used 
to stabilize the lipid dispersion. It has been found that 
the combination of emulsifiers might prevent particle 
agglomeration more efficiently 
8-9 
 
 
 
SLNs offer additional advantages as drug carrier for 
cancer targeting due to their nanoscopic size range and 
high drug loading propensity. High performance liquid 
chromatography (HPLC) is the most commonly used 
method for determining the dFdC concentration in 
plasma and tissues.
10-17
 
2 . MATERIAL AND METHODS 
2.1 Chemical and reagents 
(dFdCH) was obtained as gift sample from  Sun Pharma 
Laboratories Limited, Vadodara, India, HPLC grade 
acetonitrile and methanol (Sigma Aldrich, Mumbai, 
India) were used. Analytical reagent grade (AR) 
potassium dihydrogen orthophosphate and disodium 
phosphate (SD Fine Chemicals, Mumbai, India) (99.5% 
purity) were used. Water was purified by Millipore 
Synergy (Millipore France). The SLNs were synthesized 
by using specifically the solvent injection method. 
Mannose anchoring in SLNs was done by ring opening 
reactions followed by reaction of aldehyde groups of 
mannose in 0.1M sodium acetate buffer (pH 4.0) with 
the amines groups of SLNs to form M-SLNs
18-21 
 
 
2.2. Instruments 
For chromatography a SIL 10A auto injector HPLC 
system comprising of SCL 10A system controller, SPD 
10A prominence UV/VIS detector, and Shimadzu LC 10 
AT pump with LC Solutions software was used (all from 
Shimadzu Japan) . Separation was performed on a Luna 
Phenomenex ODS C18 HPLC column, (4.6×250 mm; 5 
µm bead size) maintained at 35°C. The pH measurement 
was carried out by Elico, model LI 120, pH meter 
equipped with a combined glass-calomel electrode. 
2.3. Chromatographic conditions 
The HPLC analysis was carried out at 35
0
C. The 
compound was chromatographed isocratically with a 
mobile phase consisting of methanol (HPLC grade): 
Acetate Buffer 0.1M (Disodium hydrogen phosphate):  
(10:90 v/v) with the apparent pH adjusted if required to 
5 ± 0.1 using Acetic Acid 0.1 M. The mobile phase was 
filtered by passing through a 0.45 µm membrane filter 
(Millipore, Bedford, MA, USA). The flow rate was 1.5 
mL/ min, and the injected volume was 20 µL. The 
effluent was monitored spectrophotometrically at 
wavelength of 269 nm 
22
.  
2.4. Preparation of standard stock and working 
solutions. 
Heparin rinsed 1 mL syringe was loaded with 0.1 mL of 
heparin solution, and the anaesthetized rats were 
selected for the standard curve preparation. Organs as 
liver, spleen, lung and kidney were removed using 
scissors and forceps, and weighed accurately. Later they 
were placed in a separate well of a tissue culture plate 
containing HEPES buffer in freezer for further studies.  
Homogenates of various organs were prepared by 
homogenizing various organs in methanol. To 1g tissues 
of organs the corresponding quantity of stock solution of 
dFdCH ranging from 100-5000 ng/mL was added. The 
contents were vortexed for 30 sec., and kept aside for 30 
min. The contents were then treated with 100 µl of 
acetonitrile to precipitate, again contents were vortexed 
for 1 min and 5 mL methanol was added to it. The 
mixture was extracted (Cole multipulse vortexer, Glas-
Col, USA) for 10 min and centrifuged at 3000 rpm for 
10 min. The supernatant was decanted into another vial 
and evaporated to dryness at 60±2 °C. The dried residue 
was reconstituted with 1 mL methanol and centrifuged at 
15000 rpm for 10 min. Clear supernatant was collected 
in vials and loaded onto the HPLC system (Figure.1). 
The standard curve data was obtained in the range of 
100 ng/mL to 5000 ng/mL(Table.1)  The HPLC column 
(C18, Shimadzu,  Japan) was washed thoroughly with 
methanol and then with mobile phase 
(Methanol/Ammonium acetate buffer; 10:90 v/v;  pH 5). 
The samples starting from blank to increasing 
concentration were injected and run through the column. 
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Figure 1: The HPLC chromatograms of dFdCH in (A) kidney, (B) liver, (C), lungs, (D), spleen, in the tissue 
extracts of Albino rats, 40 min after infusion of 1000ng/mL of dFdCH 
Table 1: HPLC standard curve data of dFdCH in different organs 
S.N Organ Conc. (ng/mL) Peak area(mm
2
 ) Regressed values       Retention Time  
                                                   1 In liver 100 5979 75056                                7 min 
2 500 10987 24372 
3 1000 61941 54846 
4 2000 113882 115795 
5 3000 180238 176744 
6 4000 239461 23694 
7 5000 297014 298643 
1 In spleen 100 4987 1721                                    7 min 
2 500 11998 24466 
3 1000 67898 57201 
4 2000 126793 122671 
5 3000 193496 188141 
6 4000 259592 252611 
7 5000 309490 319081 
1 In Lungs 100 5578 7852                                    7min 
2 500 11567 26198 
3 1000 65687 59928 
4 2000 131074 127387 
5 3000 195061 194847 
6 4000 262448 262306 
7 5000 328235 329746 
1 In Kidney 100 5765 4169                                    7min 
2 500 18907 31897 
3 1000 70946 66558 
4 2000 141995 135878 
5 3000 209938 205199 
6 4000 279784 274520 
7          5000 335769 331785 
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2.5. Biodistribution studies 
23
, (Figure. 2 a &b) 
For biodistribution studies Albino rats were divided into 
four groups with three rats in each group. Each group 
was administered with same intravenous dose of the 
formulation through tail vein (10mg/g body weight). All 
rats from each group were sacrificed at 2, 8 and 24 hr.  
The mice organs viz. spleen, kidney, liver and lungs 
were carefully removed and weighed. Each of these 
specimens was stored under freeze condition. Weighed 
tissue samples were immediately homogenized to 
separate the tissues, vortexed for 30 sec., and kept aside 
for 30 min. The contents were then treated with 100 µL 
of acetonitrile, vortexed for 1 min and then added with 5 
mL methanol. The mixture was extracted (Superfit 
vortexer, India) and centrifuged at 3000 rpm for 10 min. 
The supernatant was decanted into another vial and 
evaporated to dryness at 60°C. The dried residue was 
reconstituted with 1 mL methanol then centrifuged at 
15000 rpm for 10 min. clear supernatant was collected in 
vials and analyzed for dFdCH. (Table. 2) 
 
Figure 2a & 2b: Chromatogram of dFdC-M-SLNs and dFdC-SLNs at10 mg/g body weight of rats at 269nm in 
lungs. 
Table 2: Comparision of Calibration Standards of (free Gemcitabine) dFdCH, dFdC-PPI and dFdC –M-PPID 
using HPLC at λ max 269 nm. in kidney, lungs;  Spleen;   Liver. At 10 mg/kg body weight of albino rat 
 Time (hr) dFdCH concentration (µg/g tissue) 
Tissues 
 
 Free dFdCH 
(Mean±SD) 
dFdCH-SLNs 
(Mean±SD) 
dFdCH- M-SLNs 
(Mean±SD) 
Liver 2 335.5±4.6 204.4±4.61 156.2±4.1 
8 229.6±4.1 104.6±3.2 68.3±4.5 
24 156.2±4.3 43.8±4.1 12.5±3.8 
Spleen 2 278.9±3.1 119.8±3.5 90.95±2.1 
8 202.7±3.3 110.6±4.2 87.4±5.7 
24 169.1±3.9 59.6±2.6 79.6±3.1 
Lung 2 123.8±4.44 144.2±4.6 378.1±5.7 
8 78.6±5.2 93.2±4.32 245.2±4.5 
24 44.1±3.5 65.3±4.94 155.2±3.3 
Kidney 2 193.9±1.2 97.2±5.3 79.3±5.9 
8 78.6±3.2 58.5±4.5 22.7±4.2 
24 54.2±2.6 11.5±1.8 2.7±0.9 
 
2.6. Method validation 
24
 
The method validation was performed in following ICH 
guideline  according to which the assay validation was 
performed via various procedures including specificity, 
linearity, range, accuracy, intra-day and inter-day 
precision etc. Concentrations of dFdCH entrapped into 
SLNs and  M-SLNs were determined by three 
calibration curves run over a three week of period to 
compare the retention of drug .To determine within –run 
variation, triplicate samples at seven different 
concentrations of dFdCH were prepared in different  
tissue extracts and injected on the same day. Between – 
run variation was determined by injecting triplicate 
sample prepared at three different concentrations on 
three separate occasions. 
3. RESULT AND DISCUSSION 
3.1. High performance Liquid Chromatography 
dFdCH, monitored at their optimal UV wavelength at 
269 nm based on the UV absorption spectra .To obtain 
the best chromatographic conditions ,different column, 
mobile phase with different pH values were tested to 
provide sufficient selectivity and sensitivity. 
Chromatographic separation was performed on a C18 
reversed phase column with a mobile phase consisting 
methanol and ammonium acetate buffer (10:90v/v). The 
homogenized samples of various tissues were 
deproteinized with acetonitrile. The results were 
reproducible and the chromatogram showed a good 
resolution. 
3.2. Linearity, selectivity and sensitivity 
Calibration curves were plotted between peak area ratios 
and concentrations of dFdC in   tissues extracts of liver, 
spleen, lung and kidney respectively, the calibration 
curves were found to be linear over the concentration 
range of 100-5000 ng/mL(r
2
=0.9980, r
2
=0.9980, 
r
2
=0.9990, r
2
=1 respectively). The calibration curves 
were obtained by weighed linear regression (weighing 
factor 1/x
2
) using the Microsoft Excel 2008 software. 
The limit of quantification (LOQ), the lowest 
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concentration of the standard curve can be measured 
with acceptable accuracy and precision for the analyte 
was 200ng/mL. Limit of quantification (LOD), three 
times of the value of background noice signals was 60 
ng/ml (Figure. 3). 
Selectivity of the method was established by blank 
tissues extract spiked at 1:1 of dFdC. No significant 
interference observed at the retention time in spiked and 
blank tissue extracts. 
 
Figure 3: Calibration curves of dFdCH using HPLC at λ max 269 nm. A-lungs; B-Spleen; C-Kidney; D-Liver 
 
3.3. Recovery:  
The recovery of dFdCH (pure drug) and dFdCH 
entrapped  SLNs (dFdCH –SLNs, dFdCH -M-SLNs) in 
various tissue extracts (liver, spleen, lung and kidney 
respectively) at different concentrations was compared 
to the same concentration in methanol and ammonium 
acetate buffer (90:10 v/v). The recoveries of dFdCH, 
dFdCH-SLNs and dFdCH-M- SLNs were consistent. 
The overall recovery of all twelve extracts was 76.3%, 
78.2%, 76.3%. 78.9% for dFdC, 68.2%, 70.1%, 66.4%, 
69%, for dFdC-SLNs, 82.4%, 86.4%,85%, 83.1%, for 
dFdCH-M-SLNs. 
3.4. Stability:  
Stock solutions of 100-5000 ng/ml dFdC is stable at -
30
o
C for one month in tissue extracts but stock solutions 
of formulations at same concentrations in same medium 
is less stable. They are stable for two weeks at - 40
o
C. 
3.5. Accuracy and Precision 
Intra – day and inter – day precision and accuracy were 
determined at seven concentrations for pure drug and 
formulations. Intra -day precision was determined by 
comparing peak heights of each sample on same day 
(n=3). Inter –day precision was determined over a 3-
week period. 
4. CONCLUSION 
In this study a simple and rapid bioanalytical assay 
method has been developed and validated in various 
tissue extracts. The validated method was demonstrated 
to be accurate, precise, selective and sensitive. The 
method was found to be linear (r
2
=0.9980, r
2
=0.9980, 
r
2
=0.9990, r
2
=1 respectively) within the analytical range 
of 100-5000 ng/mL. A maximum recovery of the drug 
from the tissue extracts resulted. The present assay 
method was carried out with extensive validation 
parameters as per ICH guidelines. The drug was stable 
in extracts and developed method was used in 
biodistribution studies. The present work establishes 
suitability of mannosylated SLNs to target dFdcH in 
lungs. Encapsulation of dFdCH in mannosylated SLNs 
enhances the residence time as well as concentration of 
drug in lung which could be useful in reducing the 
dosing frequency as well as dose. This could help in 
reduction of toxicity associated with this anticancer 
bioactive.
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